Tezepelumab + Placebo
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Conditions
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Trial Timeline
May 1, 2024 → Oct 1, 2025
NCT ID
NCT06230354About Tezepelumab + Placebo
Tezepelumab + Placebo is a phase 2 stage product being developed by AstraZeneca for EGPA - Eosinophilic Granulomatosis With Polyangiitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06230354. Target conditions include EGPA - Eosinophilic Granulomatosis With Polyangiitis.
What happened to similar drugs?
0 of 1 similar drugs in EGPA - Eosinophilic Granulomatosis With Polyangiitis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06705764 | Approved | Recruiting |
| NCT06230354 | Phase 2 | Recruiting |
| NCT05062759 | Phase 3 | Completed |
Competing Products
1 competing product in EGPA - Eosinophilic Granulomatosis With Polyangiitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab | AstraZeneca | Phase 3 | 47 |